Aligos Therapeutics Enters Exclusive License Agreement With Xiamen Amoytop Biotech To Develop And Commercialize Pevifoscorvir Sodium In Greater China, With Upfront Payment Of $25M And Eligibility To Receive Up To $420M In Milestones

Under the terms of the agreement, Aligos will receive an upfront milestone of $25M USD and is eligible to receive up to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royalties on net sales in Amoytop's licensed territories. Aligos retains all development and commercialization rights for pevifoscorvir sodium in the United States, Europe, South Korea, Japan, and all other markets. In addition, Aligos will retain the right to conduct clinical trials in Greater China. With more than 90 million people living with HBV in Greater China, and given Amoytop's leadership in the Mainland China hepatology market, this agreement is expected to position pevifoscorvir sodium for greater development and regulatory success in the region. As a result of this agreement, Aligos expects that current cash, cash equivalents and investments will be extended into the fourth quarter of 2026 based on the current operating plan.